Suppr超能文献

非酒精性脂肪性肝病和肌肉减少症相加会增加死亡率:一项韩国全国性调查。

Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey.

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Dongjak-gu, Korea.

出版信息

J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):964-972. doi: 10.1002/jcsm.12719. Epub 2021 Jun 2.

Abstract

BACKGROUND

Sarcopenia is an independent risk factor not only for advanced-stage non-alcoholic fatty liver disease (NAFLD) but also for mortality. We investigated the association of sarcopenia and/or NAFLD with mortality among the Korean general population.

METHODS

Individuals aged 35-75 years without any history of cancer, ischaemic heart disease, ischaemic stroke, or secondary causes of chronic liver disease were selected from the Korean National Health and Nutrition Examination Surveys from 2008 to 2015. Their mortality data until December 2018 were retrieved from the National Death Registry. NAFLD and sarcopenia were defined by hepatic steatosis index and appendicular skeletal muscle mass divided by body mass index (BMI), respectively.

RESULTS

A total of 28 060 subjects were analysed [mean age, 50.6 (standard error, 0.1) years, 48.2 (0.3) % men]; the median follow-up duration was of 6.8 (interquartile range, 4.8, 8.4) years. NAFLD predicted mortality after adjustment for age, sex, BMI, hypertension, dyslipidaemia, and smoking (HR 1.32, 95% CI 1.03-1.70), but this prediction lost its statistical significance after additional adjustment for diabetes mellitus. In contrast, NAFLD with advanced fibrosis independently increased the risk of mortality after adjustment for all covariates (HR 1.68, 95% CI 1.02-2.79). Stratified analysis revealed that NAFLD and sarcopenia additively increased the risk of mortality as an ordinal scale (HR 1.46, 95% CI 1.18-1.81, P for trend = 0.001). The coexistence of NAFLD and sarcopenia increased the risk of mortality by almost twice as much, even after adjustment for advanced fibrosis (HR 2.18, 95% CI 1.38-3.44).

CONCLUSIONS

Concurrent NAFLD and sarcopenia conferred a two-fold higher risk of mortality. The observation that NAFLD and sarcopenia additively increase mortality suggests that risk stratification would be helpful in predicting mortality among those with metabolic derangement.

摘要

背景

肌少症不仅是晚期非酒精性脂肪性肝病(NAFLD)的独立危险因素,也是死亡的独立危险因素。我们研究了肌少症和/或 NAFLD 与韩国一般人群死亡率之间的关系。

方法

从 2008 年至 2015 年的韩国国家健康和营养检查调查中选择无癌症、缺血性心脏病、缺血性中风或慢性肝病继发原因史、年龄在 35-75 岁的个体。从国家死亡登记处检索他们截至 2018 年 12 月的死亡数据。NAFLD 和肌少症分别通过肝脂肪变性指数和四肢骨骼肌质量除以体重指数(BMI)来定义。

结果

共分析了 28060 名受试者[平均年龄 50.6(标准误差 0.1)岁,48.2(0.3)%为男性];中位随访时间为 6.8(四分位距 4.8,8.4)年。NAFLD 在调整年龄、性别、BMI、高血压、血脂异常和吸烟后预测死亡率(HR 1.32,95%CI 1.03-1.70),但在调整糖尿病后,这种预测失去了统计学意义。相反,NAFLD 伴晚期纤维化在调整所有协变量后独立增加死亡率风险(HR 1.68,95%CI 1.02-2.79)。分层分析显示,NAFLD 和肌少症按序尺度相加增加死亡率的风险(HR 1.46,95%CI 1.18-1.81,P 趋势=0.001)。即使在调整晚期纤维化后,NAFLD 和肌少症共存也会使死亡率增加近两倍(HR 2.18,95%CI 1.38-3.44)。

结论

同时存在 NAFLD 和肌少症会使死亡率增加两倍。NAFLD 和肌少症相加增加死亡率的观察结果表明,风险分层有助于预测代谢紊乱患者的死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/546c/8350204/12d5d988c018/JCSM-12-964-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验